Ebb & Flow
Aderis did not price its IPO as scheduled last week, making it the third tenuous sign at the beginning of the IPO window. The neurological company's deal is now listed as "day-to-day" on the SEC's website. The two deals that have priced - delivery/imaging play Acusphere (ACUS) and delivery company Advancis (AVNC) - both closed the week well below their offering prices. ACUS priced at $14 and closed Friday at $9.83; AVNC priced at $10 and closed at $8.90.
Jonathan Gertler, managing director and head of healthcare investment banking at Adams Harkness & Hill, still sees good demand for quality biotech paper - both follow-ons and IPOs - despite the lack of appetite for the first few IPOs. "Obviously the initial biotech offerings haven't outperformed, and they haven't clearly demonstrated the appetite for biotech issues," he said.
The Aderis news did not keep other IPO hopefuls from moving forward. Allergy and infectious disease play Dynavax filed late Friday to sell up to $90 million through Bear Stearns; Deutsche Bank; and U.S. Bancorp Piper Jaffray. And Genitope is slated to price its IPO this week, after kicking off its road show on Oct. 15. The company hopes to